Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC1 | P48995 | 2/20 | 0.67 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.67 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.67 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.67 |
| ▸ | STIM2 | Q9P246 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.66 |
| ▸ | HPGD | P15428 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21419596 | 0.91 | TRPC1 (0.68) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL8345184 | 0.90 | TRPC1 (0.67) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL2325526 | 0.89 | MAPT (0.76) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL5533620 | 0.89 | TRPC1 (0.66) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL19692480 | 0.89 | TRPC1 (0.66) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL1814204 | 0.89 | ALDH1A1 (0.67) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL12931795 | 0.88 | TRPC1 (0.66) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL2722465 | 0.88 | TRPC1 (0.64) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL21604763 | 0.88 | TRPC1 (0.64) | TRPC1TRPC3STIM1ORAI1STIM2 | |
| SCHEMBL23510303 | 0.87 | TRPC1 (0.60) | TRPC1TRPC3STIM1ORAI1STIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132158-A1 | PHENYL OXY AMIDE KINASE INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INST (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025003414-A1 | MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024077057-A1 | PHENYL OXY AMIDE KINASE INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-2668182-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2668182-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2668183-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2668183-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2668182-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC Discovery GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-8592456-B2 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation | 4SC DISCOVERY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20120196862-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196862-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2155685-B1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196862-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | IFNG, IL17A, IL2 | TRPC1 3434/4885TRPC3 1512/4885STIM1 1505/4885 |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | IFNG, IL17A, IL2 | TRPC1 3434/4885TRPC3 1512/4885STIM1 1505/4885 |
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX1 | TRPC1 190/4885TRPC3 44/4885STIM1 395/4885 |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | TRPC1 4047/4885TRPC3 4579/4885STIM1 3219/4885 |
| US-20260132158-A1 | PHENYL OXY AMIDE KINASE INHIBITORS | RAF1, CNKSR1, PHKG1 | TRPC1 3012/4885TRPC3 2602/4885STIM1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.